{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:16:30Z","timestamp":1788185790014,"version":"build-2803163510"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Dupilumab was approved for the treatment of several dermatologic immune-mediated inflammatory diseases, such as atopic dermatitis and bullous pemphigoid; whereas omalizumab is the first biological agent which was approved to treat chronic spontaneous urticaria. None of the published meta-analyses has provided the sufficient data regarding the safety of these two biologics, especially regarding their potential serious adverse events (SAEs). The aim of this study was, to comprehensively evaluate the safety of the two biologics dupilumab and omalizumab. In this study, we included 32 randomized trials, and performed meta-analyses on 113 types of SAEs regarding dupilumab and 61 types of SAEs regarding omalizumab. We identified that: (1) use of dupilumab was significantly associated with the lower incidence of atopic dermatitis, while use of omalizumab was significantly associated with the lower incidence of asthma; and (2) use of dupilumab was not significantly associated with the incidences of 112 other kinds of SAEs including various infectious diseases, while use of omalizumab was not significantly associated with the incidences of 60 other kinds of SAEs including various infectious diseases. This meta-analysis for the first time assessed the association between use of dupilumab or omalizumab and incidences of various SAEs, and identified that neither dupilumab use nor omalizumab use was associated with the increased risks of any SAEs including various infectious diseases. These findings further confirm the general safety of the two biologics dupilumab and omalizumab. This informs clinicians that there is no need to worry too much about the safety issues of these two biologics.<\/jats:p>","DOI":"10.3389\/fmed.2024.1435370","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T04:49:02Z","timestamp":1723092542000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A comprehensive analysis on the safety of two biologics dupilumab and omalizumab"],"prefix":"10.3389","volume":"11","author":[{"given":"Yu","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab.","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/biom13040634","article-title":"Dupilumab in inflammatory skin diseases: A systematic review.","volume":"13","author":"Olbrich","year":"2023","journal-title":"Biomolecules."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15120","article-title":"Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis.","volume":"34","author":"Napolitano","year":"2021","journal-title":"Dermatol Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.18176\/jiaci.0682","article-title":"Dupilumab: A review of present indications and off-label uses.","volume":"32","author":"Mu\u00f1oz-Bellido","year":"2022","journal-title":"J Invest Allergy Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.anai.2019.08.014","article-title":"New treatments for chronic urticaria.","volume":"124","author":"Kolkhir","year":"2020","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s13555-023-01040-9","article-title":"Omalizumab for patients with chronic spontaneous urticaria: A narrative review of current status.","volume":"13","author":"Casale","year":"2023","journal-title":"Dermatol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12016-020-08794-6","article-title":"Omalizumab updosing in chronic spontaneous urticaria: An overview of real-world evidence.","volume":"59","author":"Metz","year":"2020","journal-title":"Clin Rev Allergy Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/all.15030","article-title":"Eaaci biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old.","volume":"77","author":"Agache","year":"2022","journal-title":"Allergy."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jaip.2020.11.043","article-title":"Biologics for the use in chronic spontaneous urticaria: When and which.","volume":"9","author":"Maurer","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.","volume":"152","author":"Chu","year":"2023","journal-title":"J Allergy Clin Immunol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22014","article-title":"Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis.","volume":"9","author":"Chen","year":"2023","journal-title":"Heliyon."},{"key":"B12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/bjd\/ljad393","article-title":"Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.","volume":"190","author":"Drucker","year":"2024","journal-title":"Br J Dermatol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1133","article-title":"Efficacy of dupilumab plus topical corticosteroids in children with atopic dermatitis: A meta-analysis of randomized controlled trials.","volume":"12","author":"Wang","year":"2024","journal-title":"Immun Inflamm Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jdv.19797","article-title":"Comparative efficacy of oral Janus kinase inhibitors and biologics in adult Alopecia areata: A systematic review and Bayesian network meta-analysis.","volume":"38","author":"Husein-ElAhmed","year":"2024","journal-title":"J Eur Acad Dermatol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2024.100898","article-title":"Different doses and courses of omalizumab for patients with chronic spontaneous urticaria: A systematic review with meta-analysis and trial sequential analysis.","volume":"17","author":"Qin","year":"2024","journal-title":"World Allergy Organ."},{"key":"B16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jebm.12604","article-title":"Model-based meta-analysis of omalizumab in treating patients with chronic idiopathic\/spontaneous urticaria.","volume":"17","author":"Zhao","year":"2024","journal-title":"J Evid Based Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/ijd.16678","article-title":"Efficacy and safety of biological agents for pemphigoid: A systematic review and meta-analysis.","volume":"62","author":"Lin","year":"2023","journal-title":"Int J Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-world effectiveness of omalizumab in severe allergic asthma: A meta-analysis of observational studies.","volume":"9","author":"Bousquet","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/17534666231221771","article-title":"Effects of omalizumab on lung function in patients with moderate-to-severe allergic asthma: A systematic review and meta-analysis.","volume":"18","author":"Liao","year":"2024","journal-title":"Ther Adv Respir Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/1744666X.2023.2271666","article-title":"Skin infections during dupilumab monotherapy in moderate-to-severe atopic dermatitis \u2013a meta-analysis of randomized clinical trials.","volume":"20","author":"Marko","year":"2024","journal-title":"Expert Rev Clin Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","article-title":"Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events.","volume":"151","author":"Geba","year":"2023","journal-title":"J Allergy Clin Immunol."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092152","article-title":"Effectiveness and safety of immunosuppressants and biological therapy for chronic spontaneous urticaria: A network meta-analysis.","volume":"10","author":"Lin","year":"2022","journal-title":"Biomedicines."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29365","article-title":"Meta-analysis of the adoption of omalizumab in the treatment of pediatric allergic diseases.","volume":"10","author":"Xu","year":"2024","journal-title":"Heliyon."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1080\/09546634.2022.2102121","article-title":"Dupilumab for the treatment of adult atopic dermatitis in special populations.","volume":"33","author":"Patruno","year":"2022","journal-title":"J Dermatol Treat."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1435370\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T04:49:07Z","timestamp":1723092547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1435370\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":24,"alternative-id":["10.3389\/fmed.2024.1435370"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1435370","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"article-number":"1435370"}}